,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': 'Application for carnitine supplement for deficiency secondary to the ketogenic diet.', 'fs': 'Application for carnitine supplement for deficiency secondary to the ketogenic diet.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyADUA0'}, 'Id': 'a0P2P000007JyADUA0', 'Event_Date__c': '2018-02-09', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'Application for carnitine supplement for deficiency secondary to the ketogenic diet.', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArPxQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'No registered product for use in NZ, seeking further information.', 'fs': 'No registered product for use in NZ, seeking further information.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyF9UAK'}, 'Id': 'a0P2P000007JyF9UAK', 'Event_Date__c': '2018-06-18', 'Event_Description__c': 'No registered product for use in NZ, seeking further information.', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArU1QAK'}, 'change': None}]",Feb 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': 'The next meeting of the Rare Disorders Subcommittee will be held in September 2019.', 'fs': 'The next meeting of the Rare Disorders Subcommittee will be held in September 2019.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2019', 'fs': 'Aug 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyFAUA0'}, 'Id': 'a0P2P000007JyFAUA0', 'Event_Date__c': '2019-08-21', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': 'The next meeting of the Rare Disorders Subcommittee will be held in September 2019.', 'Formatted_Date__c': 'Aug 2019', 'Status_History__c': 'a132P000000AriBQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy be deferred, due to insufficient supporting evidence and uncertainty regarding the size and definition of the intended patient population. </p><p>1.1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation because, in order to fully consider this application, it would need a clearer definition of the appropriate target patient population (eg carnitine deficiency due to valproate and plasma carnitine less than 26 micromoles per litre) and evidence of effectiveness or use of levocarnitine in that defined patient population. The Subcommittee noted it would welcome a resubmission from the applicant that addresses these matters.</p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that levocarnitine for inborn errors of metabolism be funded with a high priority within the context of the rare disorders therapeutic area, subject to the following Special Authority criteria:</p><p><b style=""font-size: 10pt;"">Initial application</b><span style=""font-size: 10pt;""> – inborn errors of metabolism.</span><b style=""font-size: 10pt;""> </b><span style=""font-size: 10pt;"">Only</span><b style=""font-size: 10pt;""> </b><span style=""font-size: 10pt;"">from a metabolic physician or medical physician on the recommendation of a metabolic physician. </span></p><p><span style=""font-size: 10pt;"">Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has a confirmed primary carnitine deficiency; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Plasma carnitine levels are less than the lower limit of normal.</span></p><p><br></p><p><b style=""font-size: 10pt;"">Renewal application</b><span style=""font-size: 10pt;""> – inborn errors of metabolism. Only from a metabolic physician or on the recommendation of a metabolic physician. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.</span></p><p>1.2.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation because of the high health need of patients, especially those with carnitine transport or uptake deficiencies (eg systemic primary carnitine deficiency (CDSP)) for whom levocarnitine is the only beneficial treatment and there is evidence of harm if patients are untreated. The Subcommittee noted that a pharmaceutical-grade (GMP-certified) product or products would need to be identified in order for levocarnitine to be considered for listing in Section B of the Pharmaceutical Schedule.\xa0</p>', 'fs': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy be deferred, due to insufficient supporting evidence and uncertainty regarding the size and definition of the intended patient population. </p><p>1.1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation because, in order to fully consider this application, it would need a clearer definition of the appropriate target patient population (eg carnitine deficiency due to valproate and plasma carnitine less than 26 micromoles per litre) and evidence of effectiveness or use of levocarnitine in that defined patient population. The Subcommittee noted it would welcome a resubmission from the applicant that addresses these matters.</p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that levocarnitine for inborn errors of metabolism be funded with a high priority within the context of the rare disorders therapeutic area, subject to the following Special Authority criteria:</p><p><b style=""font-size: 10pt;"">Initial application</b><span style=""font-size: 10pt;""> – inborn errors of metabolism.</span><b style=""font-size: 10pt;""> </b><span style=""font-size: 10pt;"">Only</span><b style=""font-size: 10pt;""> </b><span style=""font-size: 10pt;"">from a metabolic physician or medical physician on the recommendation of a metabolic physician. </span></p><p><span style=""font-size: 10pt;"">Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has a confirmed primary carnitine deficiency; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Plasma carnitine levels are less than the lower limit of normal.</span></p><p><br></p><p><b style=""font-size: 10pt;"">Renewal application</b><span style=""font-size: 10pt;""> – inborn errors of metabolism. Only from a metabolic physician or on the recommendation of a metabolic physician. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.</span></p><p>1.2.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation because of the high health need of patients, especially those with carnitine transport or uptake deficiencies (eg systemic primary carnitine deficiency (CDSP)) for whom levocarnitine is the only beneficial treatment and there is evidence of harm if patients are untreated. The Subcommittee noted that a pharmaceutical-grade (GMP-certified) product or products would need to be identified in order for levocarnitine to be considered for listing in Section B of the Pharmaceutical Schedule.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that levocarnitine, the only biologically active isomer of carnitine, is not approved by Medsafe. It is considered a dietary supplement in New Zealand and can be purchased over the counter at pharmacies or online. </p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine is a compound that is synthesised in the body from amino acids and is also obtained from the diet, particularly from meat and animal products. The Subcommittee noted that carnitine transports long-chain fatty acids into the mitochondria of tissue cells, especially to skeletal and cardiac muscle cells, enabling oxidation of the fatty acids and energy metabolism. </p><p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that levocarnitine is not listed in Section B of the Pharmaceutical Schedule for community use in any indication and noted that there is no evidence of consideration by international pharmaceutical funding agencies regarding levocarnitine. The Subcommittee noted that levocarnitine is funded for hospital use in multiple dose forms (capsules, oral solution and solution for injection) and that these dose forms ensure there is a suitable formulation for use in children.</p><p>1.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that testing of total plasma carnitine is performed in New Zealand with an approximate cost of up to $150 per test. Members noted that the normal reference range for plasma total carnitine is between 35 and 60 micromoles per litre (umol/L). Members considered that plasma carnitine may not accurately reflect total body carnitine due to stores in muscle tissue. </p><p><i>Carnitine deficiency secondary to ketogenic diet</i></p><p>1.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a ketogenic diet is a high-fat, low-carbohydrate dietary regimen designed to mimic the metabolic changes that occur during fasting, and that this diet may be used as conjunctive therapy for patients with severe epilepsy who have not achieved seizure control with treatment (ie intractable epilepsy). The Subcommittee noted that about two-thirds of patients with intractable epilepsy experience a positive response to a ketogenic diet.</p><p>1.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that a therapeutic ketogenic diet may result in carnitine deficiency due to its high fat content, however, members considered that symptomatic carnitine deficiency rarely occurs due to a ketogenic diet.</p><p>1.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine deficiency has also been reported in patients with epilepsy who have received valproate, carbamazepine and phenobarbital. The Subcommittee considered that the majority of New Zealand patients with intractable epilepsy would be carnitine deficient due to use of valproate, which creates a fatty acid oxidation defect. </p><p>1.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC has received Named Patient Pharmaceutical Assessment (NPPA) applications for levocarnitine use in patients aged 5 to 12 years with carnitine deficiency secondary to a therapeutic ketogenic diet for intractable epilepsy, with requested dosages ranging from 10 mg to 50 mg per kg per day.</p><p>1.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2017-12.pdf"" target=""_blank"">December 2017</a> the Special Foods Subcommittee stated that there are two DHBs (Auckland and Canterbury) that have dedicated teams for managing patients on therapeutic ketogenic diets; and that they commence approximately 12-16 patients (at Starship Children’s Hospital) and 10-30 patients (at Christchurch Hospital) on these diets annually. Members considered that the true potential patient population in New Zealand would be higher as patients in other cities or regions are currently unable to access ketogenic diet therapy for intractable epilepsy.</p><p>1.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the applicant has estimated that there would be 20 to 30 patients per year in Christchurch. The Subcommittee noted and expressed some uncertainty about PHARMAC’s estimate of 53 patients nationally per year who might commence and respond to a therapeutic ketogenic diet (estimate weighted for response and accounts for 2 years of treatment). </p><p>1.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that this indication (carnitine deficiency secondary to a therapeutic ketogenic diet for intractable epilepsy) does not meet the definition of a rare disorder as per the second of <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/medicines-for-rare-disorders/"" target=""_blank"">PHARMAC’s Three Principles for Rare Disorders</a>.</p><p>1.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following publications regarding management of patients with intractable epilepsy who are on a ketogenic diet, and for the treatment of carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/10584968"" target=""_blank"">Vining EP. Epilepsy Res. 1999;37:181-90</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/18823325"" target=""_blank"">Kossoff et al. Epilepsia. 2009;50:304-17</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29881797"" target=""_blank"">Kosoff et al. Epilepsia Open. 2018;3:175-92</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30403286"" target=""_blank"">Martin-McGill et al. Cochrane Database Syst Rev. 2018;11:CD001903</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://media.starship.org.nz/epilepsy-guideline-2017-/epilepsy-guideline-2017-.pdf"" target=""_blank"">Epilepsy Guidelines and Pathways for Children and Young People [Internet]. New Zealand: Child and Youth Clinical Networks (NZCYCN); 2017 [cited September 2019]</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.nice.org.uk/guidance/cg137"" target=""_blank"">Epilepsies: diagnosis and management [Internet]. Clinical guideline CG137. UK: National Institute for Health and Care Excellence (NICE); Jan 2012 [revised Oct 2019; cited Sept 2019]</a></p><p>1.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is no high-quality evidence for levocarnitine supplementation for patients with carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy, but that there are uncontrolled anecdotal reports of improved wellbeing, energy levels and seizure control from the diet. </p><p>1.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted evidence from a small study investigating the long-term effects of ketogenic diets on carnitine levels as assessed at 0, 1, 6, 12, and 24 months in 38 patients on a standard ketogenic diet <a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=11879348"" target=""_blank"">(Berry-Kravis et al. Epilepsia. 2001;42:1445-51).</a> </p><p>1.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in this study, three patients had carnitine deficiency at baseline and received supplementation, carnitine decreased in the first few months of the diet and then generally stabilised in non-supplemented patients, and that 19% of patients were supplemented with levocarnitine. The Subcommittee noted that baseline carnitine status was associated with the number of antiepileptic drugs at diet initiation (P&lt;0.05) and that no patients showed clinical signs of carnitine deficiency during dietary therapy. </p><p>1.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in this study, at 1 month, some patients who did not receive levocarnitine supplementation had reduced carnitine levels and at 5 months there were mild reductions in carnitine levels for these patients, but no patients were symptomatic of carnitine deficiency. Members considered that most patients in this study were not carnitine deficient. Members considered that not all patients in this study become carnitine deficient, but that patients with borderline or low carnitine at the start of ketogenic diet therapy were at risk of carnitine deficiency while on the diet.</p><p>1.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that, if levocarnitine was to be funded for this patient group, many patients would start supplementation when their total plasma carnitine level is at or slightly below the lower limit of the normal range (35 umol/L). The Subcommittee considered that the optimal threshold for commencement of carnitine supplementation in patients on therapeutic ketogenic diets was unclear, and members considered that a threshold beneath the lower limit of normal may be more appropriate (eg total carnitine &lt;26 umol/L).</p><p>1.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients on therapeutic ketogenic diets who respond to this treatment may stay on the diet for 2 years, and considered that levocarnitine supplementation in these patients would not result in cost savings to the health system.</p><p>1.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there was insufficient evidence to support the use of levocarnitine in patients on therapeutic ketogenic diets for intractable epilepsy, and there was a lack of clarity around which patients would benefit most, how many patients this would be per year nationally, and what funding criteria should apply. The Subcommittee considered that it could review a resubmission, if received, that ideally would include an updated definition of the patient group (eg carnitine deficiency due to valproate use; symptomatic; specific agents discontinued) and an updated threshold for total plasma carnitine level (eg less than 26 umol/L), if appropriate, and evidence for use of levocarnitine in this defined patient group. Members considered that neurologists may be able to provide valuable input regarding these concerns.</p><p>1.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC had provided draft Special Authority criteria, and members considered that it would need to be revised to include any new information or evidence received at the time the funding application is reconsidered.</p><p><i>Metabolic indications: inborn errors of metabolism</i></p><p>1.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that inborn errors of metabolism are a heterogenous group of diseases that include the fatty acid oxidation disorders, which are caused by one or more genetic mutations that disrupt mitochondrial oxidation or fatty acid transport. </p><p>1.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine transport or uptake deficiencies such as systemic primary carnitine deficiency (CDSP) are sub-types of fatty acid oxidation disorders and that CDSP predominantly affect infants and children, causing death or irreversible organ damage if not treated early. The Subcommittee noted that patients with carnitine transport or uptake deficiencies cannot synthesise enough carnitine for essential requirements, and considered that these patients require levocarnitine to prevent damage from this disorder.</p><p>1.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine supplementation in fatty acid oxidation disorders (other than carnitine transport or uptake deficiencies) is debated, potentially offering benefit in secondary carnitine deficiency but in other cases may actually cause secondary carnitine deficiency due to conjugation of fatty acids with carnitine, which is then excreted. </p><p>1.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC has received NPPA applications for levocarnitine use in metabolic indications including fatty acid oxidation disorders and CDSP, with requested dosages ranging from 50 mg to 400 mg per kg per day, often in divided doses and adjusted to plasma carnitine level. The Subcommittee noted that for primary carnitine deficiency, patient age at the time of NPPA application ranged from &lt;1 to 40 years, with average age of about 11 years.</p><p>1.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC staff have inferred from the NPPA data that the prevalence of primary carnitine deficiency (severe enough to warrant supplementation) is no greater than 1:250,000 in New Zealand, and that staff had estimated that an additional 5 patients with inborn errors of metabolism would require levocarnitine supplementation in any one year. Some members considered that the patient numbers may be an overestimate. Members noted that there a higher incidence of very long chain acyl Co-A dehydrogenase deficiency, a type of inborn error of metabolism, in Māori than in non-Māori in New Zealand.</p><p>1.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that this PHARMAC-initiated application meets the definition of a rare disorder as per the second of <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/medicines-for-rare-disorders/"" target=""_blank"">PHARMAC’s Three Principles for Rare Disorders</a>. </p><p>1.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted there is limited evidence regarding levocarnitine for patients with inborn errors of metabolism, and that a 2012 Cochrane systematic review (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22336821"" target=""_blank"">Nasser et al. Cochrane Database Syst Rev. 2012; 2: CD006659</a>) identified no clinical trials that met criteria for inclusion, thus reported no conclusions regarding carnitine supplementation for patients with inborn errors of metabolism. </p><p>1.25.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following expert opinion review publications regarding treatment of carnitine deficiency due to inborn errors of metabolism:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30740404"" target=""_blank"">Merritt et al. Ann Transl Med. 2018:24;473</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/22989098"" target=""_blank"">Magoulas et al. Orphanet J Rare Dis. 2012:7;68</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/22420015"" target=""_blank"">El-Hattab et al. GeneReviews [Internet]. 2012 [updated 2016]</a><u> </u></p><p>1.25.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there are reports of improvement in metabolic decompensation and skeletal and cardiac muscle function after carnitine supplementation of patients with metabolic diseases. Members also considered that there are reports of patients with metabolic diseases who have discontinued carnitine supplementation and subsequently experienced hypoglycaemic attacks or sudden death from cardiac arrhythmia.</p><p>1.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, while there is a lack of clinical trial evidence for carnitine supplementation and that the evidence of benefit remains uncertain, carnitine supplementation may benefit some individuals, and that in cases of CDSP carnitine supplementation should be commenced quickly to prevent harm. The Subcommittee considered that maintaining high carnitine levels in patients with CDSP was important to ensure availability for critical cell functions.</p><p>1.27<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that for patients with inborn errors of metabolism other than CDSP, intermittent carnitine therapy commenced upon developing symptoms of carnitine deficiency or very low carnitine levels could control symptoms.</p><p>1.28<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that levocarnitine supplementation is generally well tolerated, noting that although there were a number of possible side effects (including diarrhoea, gastrointestinal motility, intestinal discomfort, and a fishy odour that is released in breath, sweat and urine due to production of trimethylamine) these were generally tolerated. </p><p>1.29<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that only a small proportion (about 10%) of a 100 mg per kg oral daily dose is absorbed. \xa0Higher doses may need to be utilised in very unwell patients who are metabolically unstable. </p><p>1.30<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment with levocarnitine for patients with inborn errors of metabolism may lead to stability of disease, which may result in cost savings to the health system.</p>', 'fs': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that levocarnitine, the only biologically active isomer of carnitine, is not approved by Medsafe. It is considered a dietary supplement in New Zealand and can be purchased over the counter at pharmacies or online. </p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine is a compound that is synthesised in the body from amino acids and is also obtained from the diet, particularly from meat and animal products. The Subcommittee noted that carnitine transports long-chain fatty acids into the mitochondria of tissue cells, especially to skeletal and cardiac muscle cells, enabling oxidation of the fatty acids and energy metabolism. </p><p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that levocarnitine is not listed in Section B of the Pharmaceutical Schedule for community use in any indication and noted that there is no evidence of consideration by international pharmaceutical funding agencies regarding levocarnitine. The Subcommittee noted that levocarnitine is funded for hospital use in multiple dose forms (capsules, oral solution and solution for injection) and that these dose forms ensure there is a suitable formulation for use in children.</p><p>1.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that testing of total plasma carnitine is performed in New Zealand with an approximate cost of up to $150 per test. Members noted that the normal reference range for plasma total carnitine is between 35 and 60 micromoles per litre (umol/L). Members considered that plasma carnitine may not accurately reflect total body carnitine due to stores in muscle tissue. </p><p><i>Carnitine deficiency secondary to ketogenic diet</i></p><p>1.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a ketogenic diet is a high-fat, low-carbohydrate dietary regimen designed to mimic the metabolic changes that occur during fasting, and that this diet may be used as conjunctive therapy for patients with severe epilepsy who have not achieved seizure control with treatment (ie intractable epilepsy). The Subcommittee noted that about two-thirds of patients with intractable epilepsy experience a positive response to a ketogenic diet.</p><p>1.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that a therapeutic ketogenic diet may result in carnitine deficiency due to its high fat content, however, members considered that symptomatic carnitine deficiency rarely occurs due to a ketogenic diet.</p><p>1.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine deficiency has also been reported in patients with epilepsy who have received valproate, carbamazepine and phenobarbital. The Subcommittee considered that the majority of New Zealand patients with intractable epilepsy would be carnitine deficient due to use of valproate, which creates a fatty acid oxidation defect. </p><p>1.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC has received Named Patient Pharmaceutical Assessment (NPPA) applications for levocarnitine use in patients aged 5 to 12 years with carnitine deficiency secondary to a therapeutic ketogenic diet for intractable epilepsy, with requested dosages ranging from 10 mg to 50 mg per kg per day.</p><p>1.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2017-12.pdf"" target=""_blank"">December 2017</a> the Special Foods Subcommittee stated that there are two DHBs (Auckland and Canterbury) that have dedicated teams for managing patients on therapeutic ketogenic diets; and that they commence approximately 12-16 patients (at Starship Children’s Hospital) and 10-30 patients (at Christchurch Hospital) on these diets annually. Members considered that the true potential patient population in New Zealand would be higher as patients in other cities or regions are currently unable to access ketogenic diet therapy for intractable epilepsy.</p><p>1.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the applicant has estimated that there would be 20 to 30 patients per year in Christchurch. The Subcommittee noted and expressed some uncertainty about PHARMAC’s estimate of 53 patients nationally per year who might commence and respond to a therapeutic ketogenic diet (estimate weighted for response and accounts for 2 years of treatment). </p><p>1.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that this indication (carnitine deficiency secondary to a therapeutic ketogenic diet for intractable epilepsy) does not meet the definition of a rare disorder as per the second of <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/medicines-for-rare-disorders/"" target=""_blank"">PHARMAC’s Three Principles for Rare Disorders</a>.</p><p>1.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following publications regarding management of patients with intractable epilepsy who are on a ketogenic diet, and for the treatment of carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/10584968"" target=""_blank"">Vining EP. Epilepsy Res. 1999;37:181-90</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/18823325"" target=""_blank"">Kossoff et al. Epilepsia. 2009;50:304-17</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29881797"" target=""_blank"">Kosoff et al. Epilepsia Open. 2018;3:175-92</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30403286"" target=""_blank"">Martin-McGill et al. Cochrane Database Syst Rev. 2018;11:CD001903</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://media.starship.org.nz/epilepsy-guideline-2017-/epilepsy-guideline-2017-.pdf"" target=""_blank"">Epilepsy Guidelines and Pathways for Children and Young People [Internet]. New Zealand: Child and Youth Clinical Networks (NZCYCN); 2017 [cited September 2019]</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.nice.org.uk/guidance/cg137"" target=""_blank"">Epilepsies: diagnosis and management [Internet]. Clinical guideline CG137. UK: National Institute for Health and Care Excellence (NICE); Jan 2012 [revised Oct 2019; cited Sept 2019]</a></p><p>1.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is no high-quality evidence for levocarnitine supplementation for patients with carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy, but that there are uncontrolled anecdotal reports of improved wellbeing, energy levels and seizure control from the diet. </p><p>1.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted evidence from a small study investigating the long-term effects of ketogenic diets on carnitine levels as assessed at 0, 1, 6, 12, and 24 months in 38 patients on a standard ketogenic diet <a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=11879348"" target=""_blank"">(Berry-Kravis et al. Epilepsia. 2001;42:1445-51).</a> </p><p>1.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in this study, three patients had carnitine deficiency at baseline and received supplementation, carnitine decreased in the first few months of the diet and then generally stabilised in non-supplemented patients, and that 19% of patients were supplemented with levocarnitine. The Subcommittee noted that baseline carnitine status was associated with the number of antiepileptic drugs at diet initiation (P&lt;0.05) and that no patients showed clinical signs of carnitine deficiency during dietary therapy. </p><p>1.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in this study, at 1 month, some patients who did not receive levocarnitine supplementation had reduced carnitine levels and at 5 months there were mild reductions in carnitine levels for these patients, but no patients were symptomatic of carnitine deficiency. Members considered that most patients in this study were not carnitine deficient. Members considered that not all patients in this study become carnitine deficient, but that patients with borderline or low carnitine at the start of ketogenic diet therapy were at risk of carnitine deficiency while on the diet.</p><p>1.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that, if levocarnitine was to be funded for this patient group, many patients would start supplementation when their total plasma carnitine level is at or slightly below the lower limit of the normal range (35 umol/L). The Subcommittee considered that the optimal threshold for commencement of carnitine supplementation in patients on therapeutic ketogenic diets was unclear, and members considered that a threshold beneath the lower limit of normal may be more appropriate (eg total carnitine &lt;26 umol/L).</p><p>1.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients on therapeutic ketogenic diets who respond to this treatment may stay on the diet for 2 years, and considered that levocarnitine supplementation in these patients would not result in cost savings to the health system.</p><p>1.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there was insufficient evidence to support the use of levocarnitine in patients on therapeutic ketogenic diets for intractable epilepsy, and there was a lack of clarity around which patients would benefit most, how many patients this would be per year nationally, and what funding criteria should apply. The Subcommittee considered that it could review a resubmission, if received, that ideally would include an updated definition of the patient group (eg carnitine deficiency due to valproate use; symptomatic; specific agents discontinued) and an updated threshold for total plasma carnitine level (eg less than 26 umol/L), if appropriate, and evidence for use of levocarnitine in this defined patient group. Members considered that neurologists may be able to provide valuable input regarding these concerns.</p><p>1.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC had provided draft Special Authority criteria, and members considered that it would need to be revised to include any new information or evidence received at the time the funding application is reconsidered.</p><p><i>Metabolic indications: inborn errors of metabolism</i></p><p>1.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that inborn errors of metabolism are a heterogenous group of diseases that include the fatty acid oxidation disorders, which are caused by one or more genetic mutations that disrupt mitochondrial oxidation or fatty acid transport. </p><p>1.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine transport or uptake deficiencies such as systemic primary carnitine deficiency (CDSP) are sub-types of fatty acid oxidation disorders and that CDSP predominantly affect infants and children, causing death or irreversible organ damage if not treated early. The Subcommittee noted that patients with carnitine transport or uptake deficiencies cannot synthesise enough carnitine for essential requirements, and considered that these patients require levocarnitine to prevent damage from this disorder.</p><p>1.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine supplementation in fatty acid oxidation disorders (other than carnitine transport or uptake deficiencies) is debated, potentially offering benefit in secondary carnitine deficiency but in other cases may actually cause secondary carnitine deficiency due to conjugation of fatty acids with carnitine, which is then excreted. </p><p>1.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC has received NPPA applications for levocarnitine use in metabolic indications including fatty acid oxidation disorders and CDSP, with requested dosages ranging from 50 mg to 400 mg per kg per day, often in divided doses and adjusted to plasma carnitine level. The Subcommittee noted that for primary carnitine deficiency, patient age at the time of NPPA application ranged from &lt;1 to 40 years, with average age of about 11 years.</p><p>1.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC staff have inferred from the NPPA data that the prevalence of primary carnitine deficiency (severe enough to warrant supplementation) is no greater than 1:250,000 in New Zealand, and that staff had estimated that an additional 5 patients with inborn errors of metabolism would require levocarnitine supplementation in any one year. Some members considered that the patient numbers may be an overestimate. Members noted that there a higher incidence of very long chain acyl Co-A dehydrogenase deficiency, a type of inborn error of metabolism, in Māori than in non-Māori in New Zealand.</p><p>1.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that this PHARMAC-initiated application meets the definition of a rare disorder as per the second of <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/medicines-for-rare-disorders/"" target=""_blank"">PHARMAC’s Three Principles for Rare Disorders</a>. </p><p>1.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted there is limited evidence regarding levocarnitine for patients with inborn errors of metabolism, and that a 2012 Cochrane systematic review (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22336821"" target=""_blank"">Nasser et al. Cochrane Database Syst Rev. 2012; 2: CD006659</a>) identified no clinical trials that met criteria for inclusion, thus reported no conclusions regarding carnitine supplementation for patients with inborn errors of metabolism. </p><p>1.25.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following expert opinion review publications regarding treatment of carnitine deficiency due to inborn errors of metabolism:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30740404"" target=""_blank"">Merritt et al. Ann Transl Med. 2018:24;473</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/22989098"" target=""_blank"">Magoulas et al. Orphanet J Rare Dis. 2012:7;68</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/22420015"" target=""_blank"">El-Hattab et al. GeneReviews [Internet]. 2012 [updated 2016]</a><u> </u></p><p>1.25.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there are reports of improvement in metabolic decompensation and skeletal and cardiac muscle function after carnitine supplementation of patients with metabolic diseases. Members also considered that there are reports of patients with metabolic diseases who have discontinued carnitine supplementation and subsequently experienced hypoglycaemic attacks or sudden death from cardiac arrhythmia.</p><p>1.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, while there is a lack of clinical trial evidence for carnitine supplementation and that the evidence of benefit remains uncertain, carnitine supplementation may benefit some individuals, and that in cases of CDSP carnitine supplementation should be commenced quickly to prevent harm. The Subcommittee considered that maintaining high carnitine levels in patients with CDSP was important to ensure availability for critical cell functions.</p><p>1.27<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that for patients with inborn errors of metabolism other than CDSP, intermittent carnitine therapy commenced upon developing symptoms of carnitine deficiency or very low carnitine levels could control symptoms.</p><p>1.28<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that levocarnitine supplementation is generally well tolerated, noting that although there were a number of possible side effects (including diarrhoea, gastrointestinal motility, intestinal discomfort, and a fishy odour that is released in breath, sweat and urine due to production of trimethylamine) these were generally tolerated. </p><p>1.29<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that only a small proportion (about 10%) of a 100 mg per kg oral daily dose is absorbed. \xa0Higher doses may need to be utilised in very unwell patients who are metabolically unstable. </p><p>1.30<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment with levocarnitine for patients with inborn errors of metabolism may lead to stability of disease, which may result in cost savings to the health system.</p>', 'change': None}, 'Published_Application': {'s': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a clinician application for levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy.</p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also considered levocarnitine for use in metabolic indications, specifically, for patients with inborn errors of metabolism (a PHARMAC-initiated application). </p><p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a clinician application for levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy.</p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also considered levocarnitine for use in metabolic indications, specifically, for patients with inborn errors of metabolism (a PHARMAC-initiated application). </p><p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted and agreed with the Subcommittee recommendation that levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy be deferred, due to insufficient supporting evidence and uncertainty regarding the size and definition of the intended patient population. This was a new funding application submitted by a clinician and was considered by the Rare Disorders Subcommittee. PTAC noted that the Subcommittee had made this recommendation because, in order to fully consider this application, a clearer definition was needed of the appropriate target patient population e.g. carnitine deficiency due to valproate and plasma carnitine less than 26 micromoles per litre; and evidence of effectiveness or use of levocarnitine in that defined patient population. PTAC advised that PHARMAC could seek advice from paediatric neurologists about the potential group size of patients on a therapeutic ketogenic diet for intractable epilepsy.\xa0\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted and agreed with the Subcommittee recommendation that levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy be deferred, due to insufficient supporting evidence and uncertainty regarding the size and definition of the intended patient population. This was a new funding application submitted by a clinician and was considered by the Rare Disorders Subcommittee. PTAC noted that the Subcommittee had made this recommendation because, in order to fully consider this application, a clearer definition was needed of the appropriate target patient population e.g. carnitine deficiency due to valproate and plasma carnitine less than 26 micromoles per litre; and evidence of effectiveness or use of levocarnitine in that defined patient population. PTAC advised that PHARMAC could seek advice from paediatric neurologists about the potential group size of patients on a therapeutic ketogenic diet for intractable epilepsy.\xa0\xa0</p>', 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jan 2020', 'fs': 'Jan 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Rare Disorders Subcommittee at meeting Tuesday 24 September 2019.', 'fs': 'Clinical advice received from Rare Disorders Subcommittee at meeting Tuesday 24 September 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyFBUA0'}, 'Id': 'a0P2P000007JyFBUA0', 'Event_Date__c': '2020-01-21', 'Event_Description__c': 'Clinical advice received from Rare Disorders Subcommittee at meeting Tuesday 24 September 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'Jan 2020', 'Published_Recommendation__c': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy be deferred, due to insufficient supporting evidence and uncertainty regarding the size and definition of the intended patient population. </p><p>1.1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation because, in order to fully consider this application, it would need a clearer definition of the appropriate target patient population (eg carnitine deficiency due to valproate and plasma carnitine less than 26 micromoles per litre) and evidence of effectiveness or use of levocarnitine in that defined patient population. The Subcommittee noted it would welcome a resubmission from the applicant that addresses these matters.</p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended that levocarnitine for inborn errors of metabolism be funded with a high priority within the context of the rare disorders therapeutic area, subject to the following Special Authority criteria:</p><p><b style=""font-size: 10pt;"">Initial application</b><span style=""font-size: 10pt;""> – inborn errors of metabolism.</span><b style=""font-size: 10pt;""> </b><span style=""font-size: 10pt;"">Only</span><b style=""font-size: 10pt;""> </b><span style=""font-size: 10pt;"">from a metabolic physician or medical physician on the recommendation of a metabolic physician. </span></p><p><span style=""font-size: 10pt;"">Approvals valid for 6 months for applications meeting the following criteria: </span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Patient has a confirmed primary carnitine deficiency; and</span></p><p style=""text-align: justify;""><span style=""font-size: 10pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 10pt;"">Plasma carnitine levels are less than the lower limit of normal.</span></p><p><br></p><p><b style=""font-size: 10pt;"">Renewal application</b><span style=""font-size: 10pt;""> – inborn errors of metabolism. Only from a metabolic physician or on the recommendation of a metabolic physician. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.</span></p><p>1.2.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation because of the high health need of patients, especially those with carnitine transport or uptake deficiencies (eg systemic primary carnitine deficiency (CDSP)) for whom levocarnitine is the only beneficial treatment and there is evidence of harm if patients are untreated. The Subcommittee noted that a pharmaceutical-grade (GMP-certified) product or products would need to be identified in order for levocarnitine to be considered for listing in Section B of the Pharmaceutical Schedule.\xa0</p>', 'Published_Application__c': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a clinician application for levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy.</p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee also considered levocarnitine for use in metabolic indications, specifically, for patients with inborn errors of metabolism (a PHARMAC-initiated application). </p><p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>1.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that levocarnitine, the only biologically active isomer of carnitine, is not approved by Medsafe. It is considered a dietary supplement in New Zealand and can be purchased over the counter at pharmacies or online. </p><p>1.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine is a compound that is synthesised in the body from amino acids and is also obtained from the diet, particularly from meat and animal products. The Subcommittee noted that carnitine transports long-chain fatty acids into the mitochondria of tissue cells, especially to skeletal and cardiac muscle cells, enabling oxidation of the fatty acids and energy metabolism. </p><p>1.3<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that levocarnitine is not listed in Section B of the Pharmaceutical Schedule for community use in any indication and noted that there is no evidence of consideration by international pharmaceutical funding agencies regarding levocarnitine. The Subcommittee noted that levocarnitine is funded for hospital use in multiple dose forms (capsules, oral solution and solution for injection) and that these dose forms ensure there is a suitable formulation for use in children.</p><p>1.4<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that testing of total plasma carnitine is performed in New Zealand with an approximate cost of up to $150 per test. Members noted that the normal reference range for plasma total carnitine is between 35 and 60 micromoles per litre (umol/L). Members considered that plasma carnitine may not accurately reflect total body carnitine due to stores in muscle tissue. </p><p><i>Carnitine deficiency secondary to ketogenic diet</i></p><p>1.5<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that a ketogenic diet is a high-fat, low-carbohydrate dietary regimen designed to mimic the metabolic changes that occur during fasting, and that this diet may be used as conjunctive therapy for patients with severe epilepsy who have not achieved seizure control with treatment (ie intractable epilepsy). The Subcommittee noted that about two-thirds of patients with intractable epilepsy experience a positive response to a ketogenic diet.</p><p>1.6<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that a therapeutic ketogenic diet may result in carnitine deficiency due to its high fat content, however, members considered that symptomatic carnitine deficiency rarely occurs due to a ketogenic diet.</p><p>1.7<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine deficiency has also been reported in patients with epilepsy who have received valproate, carbamazepine and phenobarbital. The Subcommittee considered that the majority of New Zealand patients with intractable epilepsy would be carnitine deficient due to use of valproate, which creates a fatty acid oxidation defect. </p><p>1.8<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC has received Named Patient Pharmaceutical Assessment (NPPA) applications for levocarnitine use in patients aged 5 to 12 years with carnitine deficiency secondary to a therapeutic ketogenic diet for intractable epilepsy, with requested dosages ranging from 10 mg to 50 mg per kg per day.</p><p>1.9<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-special-foods-subcommittee-minutes-2017-12.pdf"" target=""_blank"">December 2017</a> the Special Foods Subcommittee stated that there are two DHBs (Auckland and Canterbury) that have dedicated teams for managing patients on therapeutic ketogenic diets; and that they commence approximately 12-16 patients (at Starship Children’s Hospital) and 10-30 patients (at Christchurch Hospital) on these diets annually. Members considered that the true potential patient population in New Zealand would be higher as patients in other cities or regions are currently unable to access ketogenic diet therapy for intractable epilepsy.</p><p>1.10<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the applicant has estimated that there would be 20 to 30 patients per year in Christchurch. The Subcommittee noted and expressed some uncertainty about PHARMAC’s estimate of 53 patients nationally per year who might commence and respond to a therapeutic ketogenic diet (estimate weighted for response and accounts for 2 years of treatment). </p><p>1.11<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that this indication (carnitine deficiency secondary to a therapeutic ketogenic diet for intractable epilepsy) does not meet the definition of a rare disorder as per the second of <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/medicines-for-rare-disorders/"" target=""_blank"">PHARMAC’s Three Principles for Rare Disorders</a>.</p><p>1.12<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following publications regarding management of patients with intractable epilepsy who are on a ketogenic diet, and for the treatment of carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy:</p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/10584968"" target=""_blank"">Vining EP. Epilepsy Res. 1999;37:181-90</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/18823325"" target=""_blank"">Kossoff et al. Epilepsia. 2009;50:304-17</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/29881797"" target=""_blank"">Kosoff et al. Epilepsia Open. 2018;3:175-92</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30403286"" target=""_blank"">Martin-McGill et al. Cochrane Database Syst Rev. 2018;11:CD001903</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://media.starship.org.nz/epilepsy-guideline-2017-/epilepsy-guideline-2017-.pdf"" target=""_blank"">Epilepsy Guidelines and Pathways for Children and Young People [Internet]. New Zealand: Child and Youth Clinical Networks (NZCYCN); 2017 [cited September 2019]</a></p><p><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0</span><a href=""https://www.nice.org.uk/guidance/cg137"" target=""_blank"">Epilepsies: diagnosis and management [Internet]. Clinical guideline CG137. UK: National Institute for Health and Care Excellence (NICE); Jan 2012 [revised Oct 2019; cited Sept 2019]</a></p><p>1.13<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there is no high-quality evidence for levocarnitine supplementation for patients with carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy, but that there are uncontrolled anecdotal reports of improved wellbeing, energy levels and seizure control from the diet. </p><p>1.14<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted evidence from a small study investigating the long-term effects of ketogenic diets on carnitine levels as assessed at 0, 1, 6, 12, and 24 months in 38 patients on a standard ketogenic diet <a href=""https://www.ncbi.nlm.nih.gov/pubmed/?term=11879348"" target=""_blank"">(Berry-Kravis et al. Epilepsia. 2001;42:1445-51).</a> </p><p>1.14.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in this study, three patients had carnitine deficiency at baseline and received supplementation, carnitine decreased in the first few months of the diet and then generally stabilised in non-supplemented patients, and that 19% of patients were supplemented with levocarnitine. The Subcommittee noted that baseline carnitine status was associated with the number of antiepileptic drugs at diet initiation (P&lt;0.05) and that no patients showed clinical signs of carnitine deficiency during dietary therapy. </p><p>1.14.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in this study, at 1 month, some patients who did not receive levocarnitine supplementation had reduced carnitine levels and at 5 months there were mild reductions in carnitine levels for these patients, but no patients were symptomatic of carnitine deficiency. Members considered that most patients in this study were not carnitine deficient. Members considered that not all patients in this study become carnitine deficient, but that patients with borderline or low carnitine at the start of ketogenic diet therapy were at risk of carnitine deficiency while on the diet.</p><p>1.15<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that, if levocarnitine was to be funded for this patient group, many patients would start supplementation when their total plasma carnitine level is at or slightly below the lower limit of the normal range (35 umol/L). The Subcommittee considered that the optimal threshold for commencement of carnitine supplementation in patients on therapeutic ketogenic diets was unclear, and members considered that a threshold beneath the lower limit of normal may be more appropriate (eg total carnitine &lt;26 umol/L).</p><p>1.16<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that patients on therapeutic ketogenic diets who respond to this treatment may stay on the diet for 2 years, and considered that levocarnitine supplementation in these patients would not result in cost savings to the health system.</p><p>1.17<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there was insufficient evidence to support the use of levocarnitine in patients on therapeutic ketogenic diets for intractable epilepsy, and there was a lack of clarity around which patients would benefit most, how many patients this would be per year nationally, and what funding criteria should apply. The Subcommittee considered that it could review a resubmission, if received, that ideally would include an updated definition of the patient group (eg carnitine deficiency due to valproate use; symptomatic; specific agents discontinued) and an updated threshold for total plasma carnitine level (eg less than 26 umol/L), if appropriate, and evidence for use of levocarnitine in this defined patient group. Members considered that neurologists may be able to provide valuable input regarding these concerns.</p><p>1.18<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC had provided draft Special Authority criteria, and members considered that it would need to be revised to include any new information or evidence received at the time the funding application is reconsidered.</p><p><i>Metabolic indications: inborn errors of metabolism</i></p><p>1.19<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that inborn errors of metabolism are a heterogenous group of diseases that include the fatty acid oxidation disorders, which are caused by one or more genetic mutations that disrupt mitochondrial oxidation or fatty acid transport. </p><p>1.20<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine transport or uptake deficiencies such as systemic primary carnitine deficiency (CDSP) are sub-types of fatty acid oxidation disorders and that CDSP predominantly affect infants and children, causing death or irreversible organ damage if not treated early. The Subcommittee noted that patients with carnitine transport or uptake deficiencies cannot synthesise enough carnitine for essential requirements, and considered that these patients require levocarnitine to prevent damage from this disorder.</p><p>1.21<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that carnitine supplementation in fatty acid oxidation disorders (other than carnitine transport or uptake deficiencies) is debated, potentially offering benefit in secondary carnitine deficiency but in other cases may actually cause secondary carnitine deficiency due to conjugation of fatty acids with carnitine, which is then excreted. </p><p>1.22<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC has received NPPA applications for levocarnitine use in metabolic indications including fatty acid oxidation disorders and CDSP, with requested dosages ranging from 50 mg to 400 mg per kg per day, often in divided doses and adjusted to plasma carnitine level. The Subcommittee noted that for primary carnitine deficiency, patient age at the time of NPPA application ranged from &lt;1 to 40 years, with average age of about 11 years.</p><p>1.23<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that PHARMAC staff have inferred from the NPPA data that the prevalence of primary carnitine deficiency (severe enough to warrant supplementation) is no greater than 1:250,000 in New Zealand, and that staff had estimated that an additional 5 patients with inborn errors of metabolism would require levocarnitine supplementation in any one year. Some members considered that the patient numbers may be an overestimate. Members noted that there a higher incidence of very long chain acyl Co-A dehydrogenase deficiency, a type of inborn error of metabolism, in Māori than in non-Māori in New Zealand.</p><p>1.24<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that this PHARMAC-initiated application meets the definition of a rare disorder as per the second of <a href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/medicines-for-rare-disorders/"" target=""_blank"">PHARMAC’s Three Principles for Rare Disorders</a>. </p><p>1.25<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted there is limited evidence regarding levocarnitine for patients with inborn errors of metabolism, and that a 2012 Cochrane systematic review (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/22336821"" target=""_blank"">Nasser et al. Cochrane Database Syst Rev. 2012; 2: CD006659</a>) identified no clinical trials that met criteria for inclusion, thus reported no conclusions regarding carnitine supplementation for patients with inborn errors of metabolism. </p><p>1.25.1<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the following expert opinion review publications regarding treatment of carnitine deficiency due to inborn errors of metabolism:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/30740404"" target=""_blank"">Merritt et al. Ann Transl Med. 2018:24;473</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/22989098"" target=""_blank"">Magoulas et al. Orphanet J Rare Dis. 2012:7;68</a></p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pubmed/22420015"" target=""_blank"">El-Hattab et al. GeneReviews [Internet]. 2012 [updated 2016]</a><u> </u></p><p>1.25.2<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that there are reports of improvement in metabolic decompensation and skeletal and cardiac muscle function after carnitine supplementation of patients with metabolic diseases. Members also considered that there are reports of patients with metabolic diseases who have discontinued carnitine supplementation and subsequently experienced hypoglycaemic attacks or sudden death from cardiac arrhythmia.</p><p>1.26<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that, while there is a lack of clinical trial evidence for carnitine supplementation and that the evidence of benefit remains uncertain, carnitine supplementation may benefit some individuals, and that in cases of CDSP carnitine supplementation should be commenced quickly to prevent harm. The Subcommittee considered that maintaining high carnitine levels in patients with CDSP was important to ensure availability for critical cell functions.</p><p>1.27<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members considered that for patients with inborn errors of metabolism other than CDSP, intermittent carnitine therapy commenced upon developing symptoms of carnitine deficiency or very low carnitine levels could control symptoms.</p><p>1.28<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that levocarnitine supplementation is generally well tolerated, noting that although there were a number of possible side effects (including diarrhoea, gastrointestinal motility, intestinal discomfort, and a fishy odour that is released in breath, sweat and urine due to production of trimethylamine) these were generally tolerated. </p><p>1.29<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Members noted that only a small proportion (about 10%) of a 100 mg per kg oral daily dose is absorbed. \xa0Higher doses may need to be utilised in very unwell patients who are metabolically unstable. </p><p>1.30<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment with levocarnitine for patients with inborn errors of metabolism may lead to stability of disease, which may result in cost savings to the health system.</p>', 'PTAC_Comments__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted and agreed with the Subcommittee recommendation that levocarnitine for carnitine deficiency secondary to therapeutic ketogenic diet for intractable epilepsy be deferred, due to insufficient supporting evidence and uncertainty regarding the size and definition of the intended patient population. This was a new funding application submitted by a clinician and was considered by the Rare Disorders Subcommittee. PTAC noted that the Subcommittee had made this recommendation because, in order to fully consider this application, a clearer definition was needed of the appropriate target patient population e.g. carnitine deficiency due to valproate and plasma carnitine less than 26 micromoles per litre; and evidence of effectiveness or use of levocarnitine in that defined patient population. PTAC advised that PHARMAC could seek advice from paediatric neurologists about the potential group size of patients on a therapeutic ketogenic diet for intractable epilepsy.\xa0\xa0</p>', 'Status_History__c': 'a132P000000BPGMQA4'}, 'change': None}]",Aug 2019,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyFCUA0'}, 'Id': 'a0P2P000007JyFCUA0', 'Event_Date__c': '2020-05-15', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BlHMQA0'}, 'change': None}]",May 2020,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/request-for-information-on-the-potential-listing-of-a-range-of-medicines/"" target=""_blank"">Consultation Letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/request-for-information-on-the-potential-listing-of-a-range-of-medicines/"" target=""_blank"">Consultation Letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jan 2014', 'fs': 'Jan 2014', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyABUA0'}, 'Id': 'a0P2P000007JyABUA0', 'Event_Date__c': '2014-01-30', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/request-for-information-on-the-potential-listing-of-a-range-of-medicines/"" target=""_blank"">Consultation Letter</a></p>', 'Formatted_Date__c': 'Jan 2014', 'Status_History__c': 'a132P000000Aqa4QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2021-02-05-metabolic-disorders/"" target=""_blank"">Consultation letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2021-02-05-metabolic-disorders/"" target=""_blank"">Consultation letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2021', 'fs': 'Feb 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyFDUA0'}, 'Id': 'a0P2P000007JyFDUA0', 'Event_Date__c': '2021-02-05', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/consultation-2021-02-05-metabolic-disorders/"" target=""_blank"">Consultation letter</a></p>', 'Formatted_Date__c': 'Feb 2021', 'Status_History__c': 'a132P000000EOALQA4'}, 'change': None}]",Jan 2014,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec', 'fs': 'Dec', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyAAUA0'}, 'Id': 'a0P2P000007JyAAUA0', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Dec', 'Status_History__c': 'a132P000000Clc2QAC'}, 'change': None}, {'Summary': {'s': 'PHARMAC put out a Request For Information seeking suppliers for levocarnitine 500 mg capsule, 500 mg per 15 ml oral solution, and 200 mg per ml, 5 ml injection. This was not a proposal to list these products.', 'fs': 'PHARMAC put out a Request For Information seeking suppliers for levocarnitine 500 mg capsule, 500 mg per 15 ml oral solution, and 200 mg per ml, 5 ml injection. This was not a proposal to list these products.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2014-01-30-various-unregistered-medicines.pdf"" target=""_blank"">Consultation letter</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2014-01-30-various-unregistered-medicines.pdf"" target=""_blank"">Consultation letter</a>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2014', 'fs': 'Mar 2014', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyACUA0'}, 'Id': 'a0P2P000007JyACUA0', 'Event_Date__c': '2014-03-07', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/consultation-2014-01-30-various-unregistered-medicines.pdf"" target=""_blank"">Consultation letter</a>', 'Summary__c': 'PHARMAC put out a Request For Information seeking suppliers for levocarnitine 500 mg capsule, 500 mg per 15 ml oral solution, and 200 mg per ml, 5 ml injection. This was not a proposal to list these products.', 'Formatted_Date__c': 'Mar 2014', 'Status_History__c': 'a132P000000AqcdQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2021', 'fs': 'Apr 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyFEUA0'}, 'Id': 'a0P2P000007JyFEUA0', 'Event_Date__c': '2021-04-06', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Apr 2021', 'Status_History__c': 'a132P000000CjxYQAS'}, 'change': None}]",Dec,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': '<p><span style=""color: rgb(62, 62, 60);"">We are pleased to announce a decision to fund six treatments for people with rare metabolic disorders. Click the link below to see the treatments that will be listed on the Pharmaceutical Schedule from 1 May 2021.</span></p>', 'fs': '<p><span style=""color: rgb(62, 62, 60);"">We are pleased to announce a decision to fund six treatments for people with rare metabolic disorders. Click the link below to see the treatments that will be listed on the Pharmaceutical Schedule from 1 May 2021.</span></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p>https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-04-12-metabolic-disorders/</p>', 'fs': '<p>https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-04-12-metabolic-disorders/</p>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2021', 'fs': 'Apr 2021', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyFFUA0'}, 'Id': 'a0P2P000007JyFFUA0', 'Event_Date__c': '2021-04-12', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p>https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-04-12-metabolic-disorders/</p>', 'Summary__c': '<p><span style=""color: rgb(62, 62, 60);"">We are pleased to announce a decision to fund six treatments for people with rare metabolic disorders. Click the link below to see the treatments that will be listed on the Pharmaceutical Schedule from 1 May 2021.</span></p>', 'Formatted_Date__c': 'Apr 2021', 'Status_History__c': 'a132P000000Cl8WQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-04-12-metabolic-disorders/"" target=""_blank"">Notification Letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-04-12-metabolic-disorders/"" target=""_blank"">Notification Letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Apr 2021', 'fs': 'Apr 2021', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000007JyFGUA0'}, 'Id': 'a0P2P000007JyFGUA0', 'Event_Date__c': '2021-04-12', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2021-04-12-metabolic-disorders/"" target=""_blank"">Notification Letter</a></p>', 'Formatted_Date__c': 'Apr 2021', 'Status_History__c': 'a132P000000EODdQAO'}, 'change': None}]",Apr 2021,False,True
